Another big merger has moved closer to approval from the US Federal Trade Commission as Allergan PLC announced agreements to divest its pipeline drug brazikumab and its commercial product Zenpep (pancrelipase) in order to be acquired by AbbVie Inc.
The companies announced on 27 January that AstraZeneca PLC will acquire the IL-23 inhibitor brazikumab, in Phase IIb/III for...





